Found 6 matching trials
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX PHASE3 The aim of this adaptive Phase 3 trial is to show a statistically significa...
Show More Location
Compassionate Cancer Care Medical Group, Inc
Learn More & Join Trial
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas PHASE2 The intention of this trial is to evaluate safety and efficacy of a combina...
Show More Location
Multiple Locations
Learn More & Join Trial
Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer PHASE2 The study hypothesis is that the new drug EndoTAG-1 will improve tumor volu...
Show More Location
Institut Jules Bordet
Learn More & Join Trial
A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases PHASE2 The primary objective of study CT 4003 is to assess the behavior of EndoTAG...
Show More Location
Klinik für Internistische Onkologie in der KTB Klinik für Tumorbiologie an der Albert-Ludwigs-Universität Freiburg
Learn More & Join Trial
EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients PHASE2 The purpose of this study is to assess the efficacy, safety and tolerabilit...
Show More Location
Institut Jules Bordet - Centre des Tumeurs de l'Université Libre de Bruxelles
Learn More & Join Trial
A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer PHASE3 This is a prospective, multicenter, open-label, randomized, and controlled ...
Show More Location
Kaohsiung Veterans General Hospital
Learn More & Join Trial